This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Cancelled)
- 2. (Currently Amended) The composition according to claim 1, wherein the compound of formula I is A composition containing 11β-fluoro-17β-hydroxy-7α-methylestr-4-en-3-one or a pharmaceutically acceptable salt thereof, and

- 3. (Currently Amended) A pharmaceutical composition containing a composition according to <u>claim 2</u> <u>claim 1</u> and a pharmaceutically compatible vehicle and/or adjuvant.
- 4. (Currently Amended) The pharmaceutical composition according to claim 2, which contains elaim 3, wherein the compound of formula I is 11β -fluoro- 17β -hydroxy- 7α -methyl-estr-4-en-3-one.
 - 5. (Cancelled)

6. (Currently Amended) The A male contraceptive combination containing agent according to claim 5, wherein the compound of formula I is 11β-fluoro-17β-hydroxy-7α-methyl-estr-4-en-3-one or a pharmaceutically acceptable salt thereof, and

- 7. (Currently Amended) The male contraceptive combination agent according to claim 6 elaim-5, wherein the 11β-fluoro-17β-hydroxy-7α-methyl-estr-4-en-3-one or a pharmaceutically acceptable salt thereof androgenic compound of formula I is formulated pharmaceutically such that it is suitable to be implanted in the body of a male user such that it the androgenic compound is released continuously as an extended release formulation to the user.
- 8. (Currently Amended) The male contraceptive <u>combination</u> agent according to <u>claim 6</u> elaim 5, wherein the <u>11β-fluoro-17β-hydroxy-7α-methyl-estr-4-en-3-one or a pharmaceutically acceptable salt thereof androgenic compound of formula I is provided therein for oral administration.</u>
- 9. (Currently Amended) The male contraceptive <u>combination</u> agent according to claim 6 elaim 5, wherein the

gestagen therein is formulated pharmaceutically such that it is released to the body of the male user as an extended release formulation.

10. (Currently Amended) The male contraceptive <u>combination</u> agent according to claim 9, wherein the

formulated such that it is suitable to be implanted in the body of a male user over an extended period, such that the gestagen is released continuously as an extended release formulation to the user.

11. (Currently Amended) The male contraceptive combination agent according to claim 9 elaim 10, wherein the

gestagen is formulated such that it is suitable for administration transdermally.

12. (Currently Amended)

The male contraceptive combination agent

according to claim 6 claim 5, wherein the

gestagen is formulated for oral administration.

13-16. (Cancelled)